Molecular genetics of prostate cancer

Annals of Medicine

Volumn 33, Issue 2, 2001, Pages 130-141

  Elo, J P ^a   Visakorpi, T ^a  

^a UNIVERSITY OF TAMPERE   (Finland)

Author keywords

Chromosome; Genetic; Neoplasia; Oncogene; Prostate

Indexed keywords

ANDROGEN RECEPTOR; GLUTATHIONE TRANSFERASE; ONCOPROTEIN; PROTEIN P53; UVOMORULIN;

ARTICLE; CANCER SUSCEPTIBILITY; CHROMOSOME 16Q; CHROMOSOME 1P; CHROMOSOME 1Q; CHROMOSOME 20Q; CHROMOSOME XQ; COMPARATIVE GENOMIC HYBRIDIZATION; GENE LOCUS; GENETIC RISK; GENETIC SUSCEPTIBILITY; HETEROZYGOSITY LOSS; HUMAN; ONCOGENE; PRIORITY JOURNAL; PROSTATE CANCER; RISK FACTOR;

EID: 0035052712     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.3109/07853890109002068     Document Type: Article

References (177)

1. Carcinoma of the prostate
2. Surgical treatment of localized prostate cancer: Indications, technique and results
3. PSA decline is an independent prognostic marker in hormonally treated prostate cancer
4. A genetic model for colorectal tumorigenesis
5. Genetic basis and clonal evolution of human prostate cancer
6. Genetic instabilities in human cancers
7. Family history and the risk of prostate cancer
8. Mendelian inheritance of familial prostate cancer
9. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland
10. Cancer in twins: Genetic and nongenetic familial risk factors
11. Genetic predisposition, environment and cancer incidence: A nationwide twin study in Finland, 1976-1995
12. The impact of family history on early detection of prostate cancer
13. Evidence for autosomal dominant inheritance of prostate cancer
14. Evidence of an X-linked or recessive genetic component to prostate cancer risk
15. Segregation analysis of prostate cancer in Sweden: Support for dominant inheritance
16. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search
17. Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43
18. Evidence for a rare prostate cancer-susceptibility locus at chromosome 1p36
19. Evidence for a prostate cancer susceptibility locus on the X chromosome
20. Evidence for a prostate cancer-susceptibility locus on chromosome 20
21. A genome screen of multiplex sibships with prostate cancer
22. Combined analysis of hereditary prostate cancer linkage to 1q24-25: Results from 772 hereditary prostate cancer families from the International Consortium for Prostate Cancer Genetics
23. Linkage analyses at the chromosome 1 loci 1q24-25 (HPC1), 1q42.2-43 (PCAP), and 1p36 (CAPB) in families with hereditary prostate cancer
24. Linkage analysis of 153 prostate cancer families over a 30-cM region containing the putative susceptibility locus HPCX
25. Confirmation of prostate cancer susceptibility genes using high-risk families
26. Linkage analysis of 150 high-risk prostate cancer families at 1q24-25
27. Genetic linkage analysis of prostate cancer families to Xq27-28
28. Analysis of chromosome 1q42.2-43 in 152 families with high risk of prostate cancer
29. Prostate cancer susceptibility locus on chromosome 1q: A confirmatory study
30. Linkage analysis of 49 high-risk families does not support a common familial prostate cancer-susceptibility gene at 1q24-25
31. Prostate cancer susceptibility locus HPC1 in Utah high-risk pedigrees
32. Linkage analysis of chromosome 1q markers in 136 prostate cancer families
33. A candidate prostate cancer susceptibility gene at chromosome 17p
34. Genetics of prostate cancer: Too many loci, too few genes
35. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function
36. Evidence for a repressive function of the long polyglutamine tract in the human androgen receptor: Possible pathogenetic relevance for the (CAG)n-expanded neuronopathies
37. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer
38. Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: A population-based case-control study in China
39. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer
40. Androgen receptor variants with short glutamine or glycine repeats may identify unique subpopulations of men with prostate cancer
41. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor
42. Polymorphic repeats in the androgen receptor gene: Molecular markers of prostate cancer risk
43. Susceptibility to prostate cancer: Interaction between genotypes at the androgen receptor and prostate-specific antigen loci
44. Androgen receptor polymorphisms: Association with prostate cancer risk, relapse and overall survival
45. CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk
46. (CAG)nCAA and GGN repeats in the human androgen receptor gene are not associated with prostate cancer in a French-German population
47. Two percent of Finnish prostate cancer patients have a germ-line mutation in the hormone-binding domain of the androgen receptor gene
48. Mutated human androgen receptor gene detected in a prostatic cancer patient is also activated by estradiol
49. Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines
50. Antiproliferative effects of 1,25-dihydroxy-vitamin D3 on primary cultures of human prostatic cells
51. Vitamin D and prostate cancer: A prediagnostic study with stored sera
52. Prostate cancer risk and prediagnostic serum 25-hydroxy-vitamin D levels
53. Association of prostate cancer with vitamin D receptor gene polymorphism
54. Association of vitamin D receptor gene polymorphism with prostate cancer and benign prostatic hyperplasia in a Japanese population
55. Vitamin D receptor polymorphisms and prostate cancer
56. Association of prostate cancer with vitamin D receptor haplotypes in African-Americans
57. Vitamin D receptor polymorphisms as markers in prostate
58. Significance of vitamin D receptor gene polymorphism for prostate cancer risk in Japanese
59. Vitamin D receptor gene polymorphism in Japanese patients with prostate cancer
60. Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians
61. A polymorphism of the 5 alpha-reductase gene and its association with prostate cancer: A case-control analysis
62. Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA
63. Association of SRD5A2 genotype and pathological characteristics of prostate tumors
64. Association of HPC2/ELAC2 genotypes and prostate cancer
65. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4
66. Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect
67. Chromosomal abnormalities and related events in prostate cancer
68. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors
69. Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization
70. Mapping of chromosomal gains and losses in prostate cancer by comparative genomic hybridization
71. Comparative genomic hybridization, allelic imbalance, and fluorescence in situ hybridization on chromosome 8 in prostate cancer
72. Genetic alterations in untreated metastases and androgen independent prostate cancer detected by comparative genomic hybridization and allelotyping
73. A similar pattern of chromosomal alterations in prostate cancers from African-Americans and Caucasian Americans
74. Genetic alterations in hormone-refractory recurrent prostate carcinomas
75. Comparative genomic hybridization reveals DNA copy number gains to frequently occur in human prostate cancer
76. Identification of genetic markers for prostatic cancer progression
77. Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer
78. Loss of chromosome arm 8p loci in prostate cancer: Mapping by quantitative allelic imbalance
79. Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12-21
80. Three distinct regions of allelic loss at 13q14, 13q21-22, and 13q33 in prostate cancer
81. Genetic and chromosomal alterations in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization
82. Roles for Nkx3.1 in prostate development and cancer
83. A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer
84. Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression
85. Isolation of a candidate tumor suppressor gene on chromosome 8p21.3-p22 that is homologous to an extracellular domain of the PDGF receptor beta gene
86. Tumour-suppressor genes in prostatic oncogenesis: A positional approach
87. The FEZ1 gene at chromosome 8p22 encodes a leucine-zipper protein, and its expression is altered in multiple human tumors
88. Distinct regions of allelic loss on 13q in prostate cancer
89. Identification of two distinct deleted regions on chromosome 13 in prostate cancer
90. Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma
91. Methylation of the 5′ CpG island of the endothelin B receptor gene is common in human prostate cancer
92. Deletion at 13q21 is associated with aggressive prostate cancers
93. Human c-myc oncogene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells
94. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization
95. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays
96. Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma
97. Quantitation of MYC gene expression in sporadic breast tumors with a real-time reverse transcription-PCR assay
98. Amplification and overexpression of p40 subunit of eukaryotic translation initation factor 3 in breast and prostate cancer
99. Mapping the amplification of EIF3S3 in breast and prostate cancer
100. Prostate stem cell antigen: A cell surface marker overexpressed in prostate cancer
101. Coamplification of prostate stem cell antigen (PSCA) and MYC in locally advanced prostate cancer
102. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis
103. CG island methylation changes near the GSTP1 gene in prostatic carcinoma cells detected using the polymerase chain reaction: A new prostate cancer biomarker
104. CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia
105. Identification of three classes of cytosolic glutathione transferase common to several mammalian species: Correlation between structural data and enzymatic properties
106. Role of Mxi1 in ageing organ systems and the regulation of normal and neoplastic growth
107. Mutation of the MXI1 gene in prostate cancer
108. Loss of the chromosomal region 10q23-25 in prostate cancer
109. Point mutations of the Mxi1 gene are rare in prostate cancers
110. Commonly occurring loss and mutation of the MXI1 gene in prostate cancer
111. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway
112. The multiple roles of PTEN in tumor suppression
113. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers
114. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer
115. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome
116. Germline mutations in PTEN are present in Bannayan-Zonana syndrome
117. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer
118. PTEN/MMAC1 is infrequently mutated in pT2 and pT3 carcinomas of the prostate
119. Analysis of PTEN and the 10q23 region in primary prostate carcinomas
120. PTEN/MMAC1/TEP1 involvement in primary prostate cancers
121. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues
122. Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas
123. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts
124. Three independently deleted regions at chromosome arm 16q in human prostate cancer: Allelic loss at 16q24.1-q24.2 is associated with aggressive behaviour of the disease, recurrent growth, poor differentiation of the tumour and poor prognosis for the patient
125. Loss of heterozygosity at 16q24.1-q24.2 is significantly associated with metastatic and aggressive behavior of prostate cancer
126. Three distinct commonly deleted regions of chromosome arm 16q in human primary and metastatic prostate cancers
127. Loss of heterozygosity at chromosome 16q in prostate adenocarcinoma: Identification of three independent regions
128. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer
129. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer
130. E-cadherin: A marker for differentiation and invasiveness in prostatic carcinoma
131. Aberrant E-cadherin and alpha-catenin expression in prostate cancer: Correlation with patient survival
132. Relation between aberrant alpha-catenin expression and loss of E-cadherin function in prostate cancer
133. Reduction of E-cadherin levels and deletion of the alpha-catenin gene in human prostate cancer cells
134. Beta-catenin mutations in human prostate cancer
135. Detection and analysis of beta-catenin mutations in prostate cancer
136. Beta-catenin as oncogene: The smoking gun
137. Beta-catenin affects androgen receptor transcriptional activity and ligand specificity
138. Clinical implications of the p53 tumor-suppressor gene
139. p53 is mutated in a subset of advanced-stage prostate cancers
140. p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential
141. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma
142. A small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation
143. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
144. Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: Evidence for receptor-enhanced chemosensitivity
145. Expression of epidermal growth factor receptor and ERBB2 (HER2/neu) oncoprotein in prostatic carcinomas
146. Her-2-neu expression and progression toward androgen independence in human prostate cancer
147. Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models
148. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase
149. From HER2/Neu signal cascade to androgen receptor and its coactivators: A novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells
150. HER2 in prostate cancer-a viable target or innocent bystander?
151. Androgen receptor gene and hormonal therapy failure of prostate cancer
152. Androgen receptor and mechanism of androgen action
153. In vivo amplification of the androgen receptor gene and progression of human prostate cancer
154. Androgen receptor gene amplification: A possible molecular mechanism for androgen deprivation therapy failure in prostate cancer
155. Fluorescence in situ hybridization evaluation of c-myc and androgen receptor gene amplification and chromosomal anomalies in prostate cancer in Japanese patients
156. Methylation of the androgen receptor minimal promoter silences transcription in human prostate cancer
157. Androgen receptor gene amplification at the time of primary progression predicts response to combined androgen blockade as a second-line therapy in advanced prostate cancer
158. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor
159. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor
160. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens
161. Androgen receptor gene mutations in hormone-refractory prostate cancer
162. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer
163. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist
164. Isolation and characterization of ARA160 as the first androgen receptor N-terminal-associated coactivator in human prostate cells
165. Cloning and characterization of human prostate coactivator ARA54, a novel protein that associates with the androgen receptor
166. Cloning and characterization of androgen receptor coactivator, ARA55, in human prostate
167. Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells
168. A testis-specific androgen receptor coregulator that belongs to a novel family of nuclear proteins
169. Activation of androgen receptor function by a novel nuclear protein kinase
170. Identification of a novel RING finger protein as a coregulator in steroid receptor-mediated gene transcription
171. Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells
172. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2
173. Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss
174. The effect of castration, of estrogens and androgen injection on serum phosphatase in metastatic carcinoma of prostate